Mitoxantrona Accord (Mitoxantrone)

Mitoxantrone intercalates into DNA and blocks topoisomerase II activity, preventing the resealing of DNA strands during replication. This causes irreversible DNA damage, leading to apoptosis of rapidly dividing tumour cells.

The dose of Mitoxantrona Accord is individualized by the prescribing oncologist based on the specific cancer type, disease stage, patient weight, and organ function. Only a qualified healthcare professional should determine the regimen.

The safety of mitoxantrone in pregnancy and lactation has not been established. It is generally avoided in pregnant or nursing women because of potential fetal toxicity and unknown effects on breast‑fed infants.

To request Mitoxantrona Accord, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Mitoxantrona Accord shares the same class mechanism as other anthracenediones such as amsacrine, but it is distinguished by its broader approved indications, including both haematologic and solid tumours, and a well‑characterised safety profile that requires cardiac monitoring.

Mitoxantrona Accord should be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the solution, and ensure the temperature is continuously monitored during transport and storage.

The product is supplied as a sterile solution for injection and is administered intravenously by a qualified healthcare professional, typically over a short infusion period as directed by the treating physician.

The most serious risks include cardiotoxicity leading to reduced heart function, severe myelosuppression that can cause life‑threatening infections, and the potential development of secondary leukaemia or myelodysplastic syndromes.

Patients with known hypersensitivity to mitoxantrone or other anthracenediones, those with uncontrolled cardiac disease, and individuals who are pregnant or breastfeeding should not receive Mitoxantrona Accord unless the benefits clearly outweigh the risks.